COVID drug molnupiravir appears to be driving SARS-CoV-2 to mutate and evolve

Molnupiravir, an antiviral drug used to treat patients with COVID-19, appears to be driving SARS-CoV-2 to mutate and evolve, with some of these new viruses being transmitted onwards, a new study has shown. It is not clear, however, whether these mutated viruses pose an increased risk to patients or are able to evade the vaccine.

Related Keywords

United Kingdom ,United States ,Japan ,Cambridge ,Cambridgeshire ,South Africa ,Theo Sanderson ,Fondation Botnar ,Christopher Ruis ,Megan Craig ,Francis Crick Institute ,University Of Cambridge ,Oxford Martin School ,National Institute For Health ,Wellcome ,Research Council ,Cancer Research United Kingdom ,United Kingdom Cystic Fibrosis ,International Nucleotide Sequence Database Collaboration ,Global Initiative On Sharing All Influenza Data ,Genomics United Kingdom Consortium ,Department Of Medicine ,Care Research ,United Kingdom Consortium ,Global Initiative ,Sharing All Influenza Data ,Whilec To T ,Medical Research Council ,National Institute ,United Kingdom Cystic Fibrosis Trust ,Oxford Martin ,Covid 19 ,Cars ,Ars Cov 2 ,Antiviral Drug ,Drugs ,Revolution ,Enome ,Medicine ,Ucleotide ,Research ,Vaccine ,Virus ,